
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravir and …

ViiV Healthcare has secured its first global approval for its once-monthly treatment Cabenuva, it has emerged, to replace current antiretroviral …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

